Piersay Pharmaceutical Technology

Piersay Pharmaceutical is a biotechnology company focused on the discovery and development of targeted protein degradation (TPD) therapies. Based in Suzhou, China, the company utilizes its proprietary platform to engineer PROTACs and molecular glues that target previously "undruggable" proteins involved in cancer and autoimmune conditions. Piersay aims to overcome the limitations of traditional small molecule inhibitors by leveraging the ubiquitin-proteasome system to selectively degrade disease-driving proteins. The company's research is currently in the pre-clinical stage, supported by investment from prominent venture capital firms.